Clinicopathological features and prognosis of pyoderma gangrenosum in Korea: A single center, retrospective, observational study over 20 years.

BACKGROUND Pyoderma gangrenosum is a rare autoinflammatory neutrophilic dermatosis that rapidly evolves. However, little is known about the clinicopathological features and prognosis of pyoderma gangrenosum. AIMS We aimed to document clinicopathologic and prognostic data of the patients with pyoderma gangrenosum. METHODS In this retrospective observational study, we reviewed case records of patients diagnosed with pyoderma gangrenosum between 1999-2019. RESULTS Fifty-three patients were identified by reviewing medical records for skin biopsy; of these, 37 were men and 16 were women. Mean age at onset was 43.3 ± 18.5 years. The most frequently affected area was the lower extremities (60.4%), followed by the head and neck (17.0%). The most common subtype was ulcerative (47.2%), followed by bullous (22.6%). 30 cases had underlying diseases and the most common were malignancy (24.5%), followed by inflammatory bowel diseases (18.9%). The proportion of cases with history of trauma were significantly higher in post-operative type (100%) as compared to the bullous type (8.3%). Histologic features of granulation tissue were frequently found in post-operative type (66.7%) and bullous type (58.3%). Granulomas were predominantly found in bullous type (58.3%). Age <60 years appeared to be significantly associated with multiple lesions. Partial-to-complete remission was observed in 40 cases (75.5%). Nine (17.0%) cases experienced recurrence with a median progression-free period of six months (interquartile range of 3.0-9.0 months). Cases with underlying hematologic disorders and the bullous subtype were significantly associated with early recurrence. LIMITATIONS This study was a single-centre study with a retrospective design. CONCLUSION Pyoderma gangrenosum appears to have ethnic differences. Underlying haematologic disorders and bullous subtype have a worse prognosis. However, the type of histopathology did not correlate with the clinical outcome of pyoderma gangrenosum.

[1]  W. Lee,et al.  Cutaneous indicator of myelodysplastic syndrome: sudden bullous pyoderma gangrenosum. , 2020, Japanese journal of clinical oncology.

[2]  M. Shah,et al.  Paraneoplastic pyoderma gangrenosum in solid organ malignancy: a literature review , 2020, International journal of dermatology.

[3]  고 광필.  우리나라 위암의 역학 , 2019 .

[4]  C. Posch,et al.  Clinical characteristics and treatment outcomes of 36 pyoderma gangrenosum patients – a retrospective, single institution observation , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

[5]  Toshiyuki Yamamoto.  Epidemiology of pyoderma gangrenosum in Japanese patients by questionnaire survey , 2018, The Journal of dermatology.

[6]  A. Mostaghimi,et al.  Efficacy of Systemic Dapsone Treatment for Pyoderma Gangrenosum: A Retrospective Review. , 2018, Journal of drugs in dermatology : JDD.

[7]  C. Nelson,et al.  The Association of Age With Clinical Presentation and Comorbidities of Pyoderma Gangrenosum , 2018, JAMA dermatology.

[8]  Y. Won,et al.  Paraneoplastic Pyoderma Gangrenosum Associated with Rectal Adenocarcinoma , 2017, Annals of dermatology.

[9]  S. Chang,et al.  Two Cases of Postoperative Pyoderma Gangrenosum , 2018 .

[10]  J. Xie,et al.  The relationship between tumor necrosis factor-α polymorphisms and gastric cancer risk: An updated meta-analysis , 2017, Biomedical reports.

[11]  Y. Fujisawa,et al.  Pyoderma gangrenosum and underlying diseases in Japanese patients: A regional long‐term study , 2017, The Journal of dermatology.

[12]  J. Elfar,et al.  Pyoderma gangrenosum and inflammatory bowel disease: A cross-sectional inpatient socioeconomic study. , 2015, Journal of the American Academy of Dermatology.

[13]  D. Wetter,et al.  Pyoderma gangrenosum associated with solid organ malignancies , 2015, International journal of dermatology.

[14]  Takashi Kobayashi,et al.  Bullous pyoderma gangrenosum: A case report and review of the published work , 2012, The Journal of dermatology.

[15]  K. Shinkai,et al.  Etiology and Management of Pyoderma Gangrenosum , 2012, American Journal of Clinical Dermatology.

[16]  D. Fanoni,et al.  Role of inflammatory cells, cytokines and matrix metalloproteinases in neutrophil‐mediated skin diseases , 2010, Clinical and experimental immunology.

[17]  E. Ruocco,et al.  Pyoderma gangrenosum: an updated review , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

[18]  J. Callen,et al.  Pyoderma gangrenosum: an update. , 2007, Rheumatic diseases clinics of North America.

[19]  U. Wollina.  Pyoderma gangrenosum – a review , 2007, Orphanet journal of rare diseases.

[20]  D. I. Smith,et al.  Adalimumab treatment for pyoderma gangrenosum. , 2007, Archives of dermatology.

[21]  M. Cintra,et al.  Pyoderma gangrenosum as first clinical manifestation of gastric adenocarcinoma , 2006, Journal of the European Academy of Dermatology and Venereology : JEADV.

[22]  R. Trüeb,et al.  Pyoderma gangrenosum , 2005, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[23]  P. R. Dahl,et al.  Skin ulcers misdiagnosed as pyoderma gangrenosum. , 2002, The New England journal of medicine.

[24]  S. Shapiro,et al.  Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. , 2000, The Journal of clinical investigation.

[25]  Magne Bryne,et al.  Malignancy grading of the deep invasive margins of oral squamous cell carcinomas has high prognostic value , 1992, The Journal of pathology.

[26]  L. Brunsting,et al.  PYODERMA (ECHTHYMA) GANGRENOSUM: CLINICAL AND EXPERIMENTAL OBSERVATIONS IN FIVE CASES OCCURRING IN ADULTS , 1930 .